

Neurizon secures \$6 million cash rebate under Australian R&D Tax Incentive program for FY2025

Highlights:

- Neurizon® has secured a cash rebate of \$6.0 million from the Australian Government's Research and Development (R&D) Tax Incentive program for the 2025 financial year (FY2025), reflecting a 48.5% cash rebate on eligible R&D activities undertaken in both Australia and overseas.
- This significant rebate, a non-dilutive cornerstone of Neurizon's funding strategy, demonstrates the benefit of the Company's approved Advance & Overseas Finding (AOF).
- Neurizon previously financed \$1.5m of this rebate with Radium Capital, a specialist R&D financier, in July 2025, and has received approximately \$4.35 million in net cash upon extinguishment of this loan¹.
- Proceeds will be applied to support Neurizon's participation in the HEALEY ALS Platform Trial, with first patient dosing planned for Q1 2026.

29 January 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce it has secured a cash rebate of \$6.0 million under the Australian Government's R&D Tax Incentive program for the 2025 financial year (FY2025).

Neurizon previously financed \$1.5 million of this amount through Radium Capital, a specialist R&D financier, in July 2025, and has received approximately \$4.35 million in net cash following settlement of this loan, after interest and fees.

The 48.5% cash rebate applied to eligible R&D reflects an 18.5% uplift in the tax rate applicable to Neurizon in the FY2025². The Australian R&D Tax Rebate is an important, non-dilutive source of funding and a competitive advantage of Neurizon being based in Australia. Consistent with the funding strategy announced in December 2025³, these funds will be applied to Neurizon's participation in the HEALEY ALS Platform Trial, as part of the Company's clinical development and commercialisation readiness activities. In parallel, Neurizon continues to progress preclinical and translational programs to broaden the NUZ-001 pipeline and strengthen its potential as a platform therapy across other neurodegenerative diseases.

The R&D Tax Rebate includes a significant portion of eligible foreign R&D expenditure. Neurizon's foreign R&D activities are eligible for the R&D Tax Rebate as a result of the AOF received from AusIndustry in September 2025. The AOF is binding on the Commissioner of Taxation and AusIndustry⁴ for the 2025, 2026 and 2027 financial years and covers all pre-clinical, manufacturing, regulatory and clinical development expenditure for NUZ-001 in ALS and other neurodegenerative diseases, supporting both participation in the HEALEY ALS Platform Trial and the ongoing expansion of NUZ-001 as a potential therapy for other neurodegenerative diseases.

Chief Financial Officer, Mr Dan O'Connell commented: "This R&D Tax Rebate for the FY2025 reflects the discipline, planning and execution of the Neurizon team. The ability to apply the claim across both Australian and overseas R&D expenditure, together with a 48.5% cash rebate, underscores Neurizon's strong focus on maximizing non-dilutive sources of funding.

Securing this rebate is aligned with the funding strategy communicated in December 2025 and will directly support execution of the HEALEY ALS Platform Trial, as we progress toward first patient dosing in Q1 2026. In parallel, we continue to advance preclinical work to build the broader neurodegenerative disease pipeline.

Neurizon remains focused on delivering meaningful progress for people living with ALS and advancing NUZ-001 through the pivotal and potentially registration Phase II/III clinical program."

¹ The net amount received of \$4.35 million is net of repayment of the loan plus interest and settlement fees (total \$1.65 million).

² The tax rate applicable was 30% as a result of the type of taxable income earned by the Neurizon Therapeutics Limited consolidated group in FY2025. This higher tax rate resulted in an increase of approximately \$0.6 million in the amount of the R&D Tax Rebate received. There is no certainty that the same tax rate will apply in subsequent income years.

³ See ASX: NUZ "New Funding Secured for HEALEY ALS Platform Trial" (23 December 2025)

⁴ The AOF is binding on both AusIndustry and the Commissioner in relation to the eligibility of the activities.

-ENDS-

This announcement has been authorized for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Neurizon Therapeutics

Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Australia Investor Relations

Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

U.S. Investor Relations

Matthew Selinger
Integrous Communications
Email: mselinger@integcom.us
Phone: +1 415-572-8152

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.

This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit
<https://investorhub.neurizon.com>



Neurizon® is a registered trademark of Neurizon Therapeutics Limited